Product
risdiplam
Aliases
RO7034067
Name
EVRYSDI
INN Name
Risdiplam
FDA Approved
Yes
3 clinical trials
1 organization
2 indications
1 document
Indication
Muscular AtrophyIndication
spinalClinical trial
A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients With Spinal Muscular Atrophy After Gene TherapyStatus: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
Risdiplam - A Phase I, Open-Label, Multi-Period Crossover Study to Investigate the Safety, Food Effect, Bioavailability and Bioequivalence of Oral Doses of Two Different Formulations in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-01-28
Clinical trial
A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyStatus: Recruiting, Estimated PCD: 2027-01-31
Document
DailyMed Label: EVRYSDIOrganization
Genentech Inc.